Month: January 2022

Press release no 2, 2022 Søborg 28, 2022Konsolidator releases ERP integration Center to enable easy connections to global cloud ERP systems  Today, Konsolidator launched a new product – a cloud ERP integration center to enable easy connections to global cloud ERP systems and reach a broader customer base in line with the newly released strategy “Unfolding the potential”. The ERP integration center allows users worldwide to quickly transfer financial data directly from their ERP system as Microsoft Business Central to Konsolidator, thereby improving data accessibility, quality, and productivity in the consolidation process. With the release, enterprises who use multiple ERP systems can upload all their financial data from the entire group to Konsolidator within seconds.Simplifying the consolidation process “We constantly...

ANNOUNCEMENT NO. 25 – 28 JANUARY 2022 Under Article 19 of the Market Abuse Regulation Dampskibsselskabet NORDEN A/S is required to report transactions in Dampskibsselskabet NORDEN A/S’ shares by persons discharging managerial responsibilities and their close relatives. With reference to announcement no. 5/2019 the following restricted shares have vested:Name:   Jan RindboReason:   Reporting duty, CEOIssuer:   Dampskibsselskabet NORDEN A/SISIN code:   DK0010269844Instrument:   Restricted sharesTransaction:   Vesting of sharesVesting date:   28 January 2022Market:   Nasdaq CopenhagenNumber:   15,343Holding after transaction   99,937Name:   Martin BadstedReason:   Reporting duty, CFOIssuer:   Dampskibsselskabet NORDEN A/SISIN code:   DK0010269844Instrument:   Restricted sharesTransaction:   Vesting...

Oxford Biomedica and Homology Medicines to establish Oxford Biomedica Solutions LLC, a new U.S.-based AAV Manufacturing and Innovation Business  Homology Medicines to receive $130 million from Oxford Biomedica to continue to advance its three clinical programs and genetic medicines platform Oxford Biomedica to invest $50 million to fund the growth of Oxford Biomedica Solutions LLC and will own 80%, with Homology Medicines to own 20%; Homology Medicines to secure preferred key customer status Dr. Roch Doliveux to become Interim CEO of Oxford Biomedica and John Dawson to retire as CEO and remain a Board Director of Oxford Biomedica Oxford Biomedica and Homology Medicines to host webcasts today to discuss the announcement OXFORD, United Kingdom and BEDFORD, Mass., Jan. 28, 2022 (GLOBE NEWSWIRE) — Oxford Biomedica plc (LSE:OXB) (“Oxford...

Company announcement 02/2022 Reporting of transaction made by person discharging managerial responsibilities in NNIT’s shares NNIT A/S (“NNIT”), a leading provider of IT services and consultancy, announces that in connection with delivery of shares related to a sign on incentive, NNIT has pursuant to article 19 of the Market Abuse Regulation received notification of the below transactions by person with managerial responsibilities in NNIT. 1 Details of the reporting person and their closely associated personsa)Name: Pernille Fabricius 2 Reason for the notification a)Position/status: Executive Vice President, CFOb)Initial notification/amendment: Initial notification3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a)Name: NNIT A/Sb)LEI: 549300KM8QVF7WR406644 Details of the transaction(s):...

Company announcement 01/2022: Financial report for 2021 2021 financial performance in line with guidance – Revenue growth of 1.7% to DKK 2,877m and an operating profit margin before special items of 4.9% Performance highlights for the fourth quarter 2021Revenue of DKK 738m, down 1.5% (-6.7% organic) from Q4 2020, driven by:Life Sciences (excluding Novo Nordisk Group) grew to DKK 262m, up 29% (7% organic). The increase was related to the continued significant growth of the Life Sciences International business, where revenues increased by 47% (14% organic) to DKK 200m, while revenue from Life Sciences Denmark decreased by 7.5% to DKK 62m. Novo Nordisk Group revenue declined 27% to DKK 153m mainly explained by the Global infrastructure management agreement effective from July 1, 2021. Private & Public business revenue declined by...

Oslo, Norway – 28 January 2022 – IDEX Biometrics ASA is entering a development agreement with MKSmart, world-leading high technology provider of smart card solutions for financial payments, access control, and government identification in Southeast Asia. This partnership will provide banks and other payment card issuers access to biometric smart cards with industry leading performance and cost efficient solution.  MKSmart is ranked among the Top 10 largest card manufacturers globally, and one of six card manufacturers worldwide being fully certified by VISA, Mastercard, China UnionPay, JCB, UPI, and GSMA. Based on the turnkey card reference design from IDEX Biometrics and Infineon Technologies AG, this comprehensive solution includes the IDEX Biometrics TrustedBioÒ sensor module, which includes a proprietary ASIC delivering...

AKVA group ASA hereby invites you to the presentation of the Q4 2021 financial results, which will take place as follows: Time: Friday February 11th, 2022 at 10:00 CET. Place: Danske bank, Bryggetorget 4, Oslo.In addition to the physical presentation in Oslo, the event will be live streamed: https://channel.royalcast.com/landingpage/hegnarmedia/20220211_9/ The presentation will be held in English and due to COVID-19 restrictions the physical presentation will be open to a maximum of 20 participants. Registration for the physical presentation can be submitted to marito@danskebank.comDated: 28 January 2022                      AKVA group ASA Web: www.akvagroup.com CONTACTS:Knut Nesse Chief Executive OfficerPhone: +47 51 77 85 00Mobile: +47 91 37 62 20E-mail: knesse@akvagroup.comRonny Meinkøhn Chief Financial OfficerPhone: +47...

Mikael Norin has decided to leave his position as Group CEO of Cavotec. Norin is expected to leave the Company later in the year when a successor is in place. “Mikael has expressed his desire to return home to the US, after having been based in Switzerland with his family for the last five years, says Patrik Tigerschiold, Chairman of the Board of Cavotec”. “Mikael has done a great job of transforming Cavotec but we understand the family considerations that have led him to this decision. The board has therefore accepted his request to leave the company and we will immediately start the work to identify a successor.” “It has been the privilege of a lifetime to lead the transformation of Cavotec from a traditional product manufacturing company to a focused cleantech solution provider”, commented Mikael Norin.  Norin continued, “As this journey...

AB Amber Grid, legal entity code: 303090867. Address: Laisvės pr. 10, LT-04215 Vilnius, Lithuania. The Board of Amber Grid and the Board of the holding company EPSO-G decided to announce the selection of a strategic partner for the subsidiary gas exchange GET Baltic. Strategic partner would be offered to acquire a stake in the Company. A public tender will be held to select the most experienced strategic partner which is expected to offer gas market participants a modern, advanced solutions-based gas trading platform that includes both short-term and long-term products and clearing services in line with the best market practices. An international tender will be held to ensure competition between participants. Its documents will be published on 1 February 2022 on the website of Amber Grid. It is planned that a strategic partner will be...

Oxford Biomedica broadens leading viral vector offerings by incorporating Homology Medicines’ established AAV capabilities into a newly formed AAV Manufacturing and Innovation Business in the US with Homology Medicines as 20% ownerOxford Biomedica and Homology Medicines to establish Oxford Biomedica Solutions LLC, a new US–based AAV manufacturing and innovation businessHomology Medicines to receive $130 million from Oxford Biomedica to continue to advance its three clinical programmes and genetic medicines platformOxford Biomedica to invest $50 million to fund the growth of Oxford Biomedica Solutions LLC and will own 80%, with Homology Medicines to own 20%; Homology Medicines to secure preferred key customer statusDr. Roch Doliveux to become Interim CEO of Oxford Biomedica and John Dawson to retire as CEO and remain a Board...